Edward Tenthoff
Stock Analyst at Piper Sandler
(3.23)
# 1,072
Out of 5,132 analysts
195
Total ratings
41.71%
Success rate
3.9%
Average return
Main Sectors:
Stocks Rated by Edward Tenthoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IPSC Century Therapeutics | Maintains: Overweight | $2 → $4 | $1.75 | +128.57% | 9 | Jan 20, 2026 | |
| GLUE Monte Rosa Therapeutics | Reiterates: Overweight | $28 → $37 | $17.92 | +106.47% | 4 | Jan 14, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Overweight | $100 → $110 | $63.82 | +72.36% | 14 | Jan 13, 2026 | |
| ACRV Acrivon Therapeutics | Maintains: Overweight | $6 → $8 | $1.63 | +390.80% | 1 | Jan 9, 2026 | |
| CAPR Capricor Therapeutics | Reiterates: Overweight | $20 → $45 | $22.45 | +100.45% | 2 | Dec 10, 2025 | |
| KYMR Kymera Therapeutics | Reiterates: Overweight | $98 → $125 | $82.34 | +51.81% | 5 | Dec 9, 2025 | |
| FULC Fulcrum Therapeutics | Reiterates: Overweight | $16 → $23 | $10.63 | +116.37% | 6 | Dec 8, 2025 | |
| MRNA Moderna | Reiterates: Overweight | $69 → $63 | $42.23 | +49.18% | 13 | Nov 21, 2025 | |
| INO Inovio Pharmaceuticals | Reiterates: Overweight | $5 → $6 | $1.61 | +272.67% | 2 | Nov 14, 2025 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Overweight | $449 → $489 | $314.40 | +55.53% | 15 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $15 → $12 | $8.58 | +39.86% | 1 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $12 | $3.85 | +211.69% | 2 | Sep 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $15 | $13.10 | +14.50% | 5 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $105 | $53.07 | +97.85% | 7 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 | $16.16 | +23.76% | 7 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $7 | $1.25 | +460.00% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 → $14 | $11.65 | +20.17% | 7 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $48 | $15.54 | +208.88% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $15 → $24 | $16.67 | +43.97% | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $78 | $17.58 | +343.69% | 4 | Dec 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $30 | $11.60 | +158.62% | 4 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $65 | $2.36 | +2,654.24% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $0.72 | +2,663.19% | 3 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.23 | +143.90% | 6 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $3 | $0.31 | +873.87% | 4 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $4 → $6 | $1.25 | +380.00% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.70 | +194.12% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $224 → $248 | $57.72 | +329.66% | 5 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $3.41 | +2,539.30% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $180 | $8.47 | +2,025.15% | 3 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $44 | $17.61 | +149.86% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $37 | $5.24 | +606.11% | 2 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40,439,520 → $11,721,600 | $6.71 | +174,688,424.59% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $250 → $354 | $821.96 | -56.93% | 4 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $323 | $491.47 | -34.28% | 6 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $80 → $25 | $10.30 | +142.72% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $36 | $43.92 | -18.03% | 2 | Feb 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $25 | $1.43 | +1,648.25% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $150 | $0.59 | +25,319.42% | 1 | Jan 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $13,800 | $0.23 | +5,955,877.56% | 1 | Dec 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $803.17 | - | 11 | Feb 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $882 → $1,064 | $10.29 | +10,240.14% | 2 | Apr 15, 2013 |
Century Therapeutics
Jan 20, 2026
Maintains: Overweight
Price Target: $2 → $4
Current: $1.75
Upside: +128.57%
Monte Rosa Therapeutics
Jan 14, 2026
Reiterates: Overweight
Price Target: $28 → $37
Current: $17.92
Upside: +106.47%
Arrowhead Pharmaceuticals
Jan 13, 2026
Reiterates: Overweight
Price Target: $100 → $110
Current: $63.82
Upside: +72.36%
Acrivon Therapeutics
Jan 9, 2026
Maintains: Overweight
Price Target: $6 → $8
Current: $1.63
Upside: +390.80%
Capricor Therapeutics
Dec 10, 2025
Reiterates: Overweight
Price Target: $20 → $45
Current: $22.45
Upside: +100.45%
Kymera Therapeutics
Dec 9, 2025
Reiterates: Overweight
Price Target: $98 → $125
Current: $82.34
Upside: +51.81%
Fulcrum Therapeutics
Dec 8, 2025
Reiterates: Overweight
Price Target: $16 → $23
Current: $10.63
Upside: +116.37%
Moderna
Nov 21, 2025
Reiterates: Overweight
Price Target: $69 → $63
Current: $42.23
Upside: +49.18%
Inovio Pharmaceuticals
Nov 14, 2025
Reiterates: Overweight
Price Target: $5 → $6
Current: $1.61
Upside: +272.67%
Alnylam Pharmaceuticals
Oct 31, 2025
Reiterates: Overweight
Price Target: $449 → $489
Current: $314.40
Upside: +55.53%
Oct 9, 2025
Reiterates: Overweight
Price Target: $15 → $12
Current: $8.58
Upside: +39.86%
Sep 15, 2025
Maintains: Overweight
Price Target: $18 → $12
Current: $3.85
Upside: +211.69%
Jul 15, 2025
Maintains: Overweight
Price Target: $36 → $15
Current: $13.10
Upside: +14.50%
Jun 27, 2025
Reiterates: Overweight
Price Target: $105
Current: $53.07
Upside: +97.85%
Jun 16, 2025
Upgrades: Overweight
Price Target: $20
Current: $16.16
Upside: +23.76%
Jun 3, 2025
Assumes: Overweight
Price Target: $7
Current: $1.25
Upside: +460.00%
May 2, 2025
Reiterates: Overweight
Price Target: $24 → $14
Current: $11.65
Upside: +20.17%
Feb 28, 2025
Maintains: Overweight
Price Target: $53 → $48
Current: $15.54
Upside: +208.88%
Feb 7, 2025
Reiterates: Overweight
Price Target: $15 → $24
Current: $16.67
Upside: +43.97%
Dec 30, 2024
Reiterates: Overweight
Price Target: $78
Current: $17.58
Upside: +343.69%
Dec 2, 2024
Upgrades: Overweight
Price Target: $20 → $30
Current: $11.60
Upside: +158.62%
Nov 13, 2024
Maintains: Overweight
Price Target: $104 → $65
Current: $2.36
Upside: +2,654.24%
Sep 20, 2024
Reiterates: Overweight
Price Target: $20
Current: $0.72
Upside: +2,663.19%
Sep 17, 2024
Reiterates: Overweight
Price Target: $3
Current: $1.23
Upside: +143.90%
Jul 26, 2024
Maintains: Overweight
Price Target: $8 → $3
Current: $0.31
Upside: +873.87%
Jun 17, 2024
Upgrades: Overweight
Price Target: $4 → $6
Current: $1.25
Upside: +380.00%
Mar 5, 2024
Maintains: Overweight
Price Target: $6 → $5
Current: $1.70
Upside: +194.12%
Aug 14, 2023
Maintains: Overweight
Price Target: $224 → $248
Current: $57.72
Upside: +329.66%
Dec 12, 2022
Initiates: Overweight
Price Target: $90
Current: $3.41
Upside: +2,539.30%
Sep 7, 2022
Maintains: Overweight
Price Target: $140 → $180
Current: $8.47
Upside: +2,025.15%
Aug 25, 2022
Maintains: Overweight
Price Target: $37 → $44
Current: $17.61
Upside: +149.86%
May 23, 2022
Maintains: Overweight
Price Target: $76 → $37
Current: $5.24
Upside: +606.11%
May 13, 2022
Maintains: Overweight
Price Target: $40,439,520 → $11,721,600
Current: $6.71
Upside: +174,688,424.59%
Nov 29, 2021
Upgrades: Overweight
Price Target: $250 → $354
Current: $821.96
Upside: -56.93%
Jul 30, 2021
Maintains: Overweight
Price Target: $261 → $323
Current: $491.47
Upside: -34.28%
May 7, 2021
Downgrades: Neutral
Price Target: $80 → $25
Current: $10.30
Upside: +142.72%
Feb 16, 2021
Maintains: Overweight
Price Target: $33 → $36
Current: $43.92
Upside: -18.03%
May 12, 2020
Downgrades: Neutral
Price Target: $50 → $25
Current: $1.43
Upside: +1,648.25%
Jan 27, 2020
Initiates: Overweight
Price Target: $150
Current: $0.59
Upside: +25,319.42%
Dec 11, 2017
Initiates: Overweight
Price Target: $13,800
Current: $0.23
Upside: +5,955,877.56%
Feb 13, 2017
Upgrades: Overweight
Price Target: n/a
Current: $803.17
Upside: -
Apr 15, 2013
Maintains: Neutral
Price Target: $882 → $1,064
Current: $10.29
Upside: +10,240.14%